Mott Capital Management, an investment research and management firm, released its “Thematic Growth Strategy” Q3 2026 investor ...

Biotechnology firm Illumina secured a selection to support the SG-INSIGHT clinical study, expanding whole-genome sequencing ...

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on ...

Illumina Inc. had been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine programme. The study is ...

Illumina, Inc. reported financial results for the third quarter of fiscal year 2026, with reported revenue of $1.13 billion, ...

Shares of Illumina Inc. plunged 18.64% to $235.99 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 1.82% to 7,580.07 and Dow Jones ...

Full-year 2026 revenue and EPS guidance were raised to reflect Q3 outperformance and an expected increase in sequencing consumable revenue from the expanded NovaSeq X installed base. Management ...

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Illumina , Alignment Healthcare and Stryker with bullish sentiments. Illumina (ILM ...

GRAIL (GRAL) offers MCED screening tests that offer employers economic value and employee health clarity. Divestiture of GRAIL by Illumina offers investors $8B valuation foundation. TAM valuation ...

This was the stock's fourth consecutive day of gains.